New health technology accelerator programme launches as successful start-ups enter the Greater Manchester Future of Health Challenge
Frimley, September 11th, 2019 – Novartis today announced the launch of the Greater Manchester Future of Health Challenge and named the start-up businesses selected to participate. This intensive 12-week programme will include training, mentoring and support from leaders in the health and technology space, including Novartis, Google and Salford Royal NHS Foundation Trust, to create new clinical solutions for patients in Greater Manchester and beyond.
Fifteen participants were selected from over 100 applicants who replied to the call for creative use of new technologies to solve some of Greater Manchester’s most pressing health problems. In addition to access to world-class support and expertise, participating start-up companies also have a chance to receive cloud space and additional expert support from Google Cloud for Startups.
“Medicine is being revolutionised by increasing use of digital technology and data science, and we are committed to using our expertise and resources to unlock the opportunities this offers,” said Emma Hoglund, Head of Commercial Execution and Digital Strategy at Novartis UK. “This programme is part of a wider initiative to collaborate with like-minded organisations to create new ideas, solutions and technologies that can help our NHS to provide better patient care. We are pleased to be able to support this programme and wish the participants every success with their projects.”
“I have been hugely impressed by the volume and the quality of the businesses that applied for a place on the Greater Manchester Future of Health Challenge”, said Danny Meaney, Founder and CEO of UP Ventures. “I think the response we got bears testimony to Greater Manchester’s fast growing international reputation as a great place to grow early stage tech businesses.”
Developmental projects entering the programme range from advanced visualisation software and tools to help improve cognition, to home-based care systems that support elderly independent living and a remote thermometer which requires no contact with the patient.
The end of the programme will be marked by an event at The Landing, MediaCityUK in December where participants will showcase what they have learned and their progress towards addressing some of the health challenges within Greater Manchester.
Notes to editor
About the Greater Manchester Future of Health Challenge
The Greater Manchester Future of Health Challenge is an initiative to identify new solutions based on digital technologies to address some of the most pressing public health problems in the Greater Manchester area. It is a collaboration between Up Ventures, MediaCityUK, Salford Royal NHS
Foundation Trust, Salford Digital, Health Innovation Manchester, Novartis, Push Doctor, Google, and Apadmi.
The programme asked applicant health technology start-ups and entrepreneurs to submit ideas that could be beneficial to one or more of three focus areas as selected by local health leaders:
Solutions that improve the experience of those with Dementia and/or Frailty
Solutions allowing primary care and outpatient services to be delivered in or near the home for patients
Innovations to allow Digital Nudges to improve Prevention and Public Health
Fifteen participants were selected from hundreds of applicants. Successful businesses participating in the programme are:
BuddyHub exists to reduce loneliness and isolation in older people (50+) and promote a more active lifestyle. By using smart technology they better and more efficiently match ‘Members ' to ‘Buddy’ volunteers, helping to create a new sustainable friendship circle that is rewarding for everyone.
Cievert is a web-based platform that tackles the problems surrounding routine patient follow-up, in particular driving efficiencies and improvement of care for those with long-term conditions.
Collabco’s myday platform is designed to improve engagement between users (general public) and providers to improve communication between the user types and enable information sharing and data capture on a global scale.
Evergreen Life is a Personal Health Platform allowing people to own their own health records and interact with the health and care system which is then combined with digital nudges, advice and coaching. It also enables the sharing of information with trusted family members and carers to support personal care or the care of others.
Flock is aimed at people suffering from type two diabetes, obesity, and smoking or alcohol addiction. It uses a unique approach to digital profiling to define what each individual is motivated by and provides a pattern of digital nudges designed specifically for each individual.
Gendius is a platform that uses artificial intelligence to calculate an individual’s risk of developing complications from diabetes. The associated secure dashboard enables healthcare professionals to track and monitor patients with the highest need and the hints and tips educate the patient around self-care and prevention of secondary complications.
GiveVision’s SightPlus is a clinically validated low vision aid that helps visually impaired people to see up close and at a distance, thus enabling patients with long-term conditions such as AMD, Diabetes or retinopathy that require regular attendance at outpatient clinics. It has already helped hundreds of low vision patients to improve their sight and work and live independently.
Healum solutions are intended for people with long-term conditions and use behaviour change interventions to improve lifestyle and support people to self-manage their conditions with support from healthcare professionals when outside the clinical environment.
Holovis builds some of the world’s most advanced visualisation and software solutions by bringing together sensing technology, data analytics, and multi-sensory, immersive interactivity to solve problems and measure and monitor patients responses and wellbeing.
Howz is a smart home system designed to help older people suffering from conditions such as dementia or frailty to stay independent for longer by alerting systems. It learns a person’s daily routine and uses this to detect short term anomalies and long term changes.
ImproveWell is a quality improvement platform designed to empower frontline staff to drive change using technology that focuses on identifying operational efficiencies to improve the management of experiences and outcomes for patients. From the ward to the board, everyone can make suggestions to improve their workplace.
Konsie is bringing Artificial Intelligence (AI) into the home to support elderly independent living, dramatically reducing injuries and loss of independence associated with falls, strokes and immobilising conditions. This helps to maintain wellbeing, health and saves public funds by reducing hospital and care dependency.
MindMoose helps children understand how their brain works and to develop healthy self-awareness and self-esteem by using fun, interactive digital tools to support early intervention and prevention in children's mental health. It improves the availability of high-quality, evidence-based resources for the prevention and early intervention treatment in children's mental health.
MyCognition is dedicated to understanding and improving cognition. Taking a research-based approach has resulted in has an NHS approved, MHRA accredited (CE Mark) device platform that allows a user to comprehensively track, change and consolidate their cognitive health, strengthening their health and mental resilience.
TriMedika is an innovative thermometer that uses no consumables and has zero contact with the patient (infection control and patient comfort). The thermometer delivers cost and time savings for nurses and reducing hospital infections & plastic waste.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments.
About 105 000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
In the UK, we employ approximately 1,500 people to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis. Since 2014, Novartis has invested over £200 million in R&D and is a leading sponsor of clinical trials, in the UK. For more information, please visit www.novartis.co.uk
Novartis UK is on Twitter. Sign up to follow @NovartisUK at https://twitter.com/novartisuk